BARD1 Life Sciences Ltd
ASX:BD1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BARD1 Life Sciences Ltd
Operating Income
BARD1 Life Sciences Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BARD1 Life Sciences Ltd
ASX:BD1
|
Operating Income
-AU$6.6m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-119%
|
CAGR 10-Years
N/A
|
|
|
Sonic Healthcare Ltd
ASX:SHL
|
Operating Income
AU$976.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
6%
|
|
|
Integral Diagnostics Ltd
ASX:IDX
|
Operating Income
AU$71.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Australian Clinical Labs Ltd
ASX:ACL
|
Operating Income
AU$68m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Apiam Animal Health Ltd
ASX:AHX
|
Operating Income
AU$12.4m
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
H
|
Healius Ltd
ASX:HLS
|
Operating Income
AU$17.6m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-14%
|
|
BARD1 Life Sciences Ltd
Glance View
BARD1 Life Sciences Ltd. is a biotechnology company, which engages in the provision of medical services. The firm is engaged in research, development, and commercialization of non-invasive diagnostic products for the early detection of cancer. The Company’s technologies include BARD1, SubB2, NET and hTERT. BARD1 is a biomarker platform covering various tumor markers including nucleic acids, proteins, and autoantibodies for early cancer diagnosis.SubB2M is a pan-cancer probe for monitoring cancer treatment response and recurrence across a wide range of cancers. NET is designed to capture and purify biomarkers, including acids, cells, and exosomes. hTERT is an antibody-based assay to detect hTERT, a component of telomerase, in cells.
See Also
What is BARD1 Life Sciences Ltd's Operating Income?
Operating Income
-6.6m
AUD
Based on the financial report for Jun 30, 2021, BARD1 Life Sciences Ltd's Operating Income amounts to -6.6m AUD.
What is BARD1 Life Sciences Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-119%
Over the last year, the Operating Income growth was -183%. The average annual Operating Income growth rates for BARD1 Life Sciences Ltd have been -51% over the past three years , -119% over the past five years .
